Researchers at Pitt are investigating the use of a ‘stop scarring’ signaling molecule decorin, a small leucine-rich proteoglycan, as a therapeutic to reduce scarring. The extracellular matrix (ECM) and its associated components are important in cutaneous wound healing. Compelling data in in a mouse model of hypertrophic scarring supports the important role of decorin as a regulator of collagen fibrillogenesis and a non-competitive inhibitor of multiple growth factors signaling cascades.